迈威生物注射用7MW4911临床试验申请获FDA许可

Core Viewpoint - Maiwei Biotech has received FDA approval for the clinical trial application of its innovative antibody-drug conjugate (ADC) 7MW4911, which targets cadherin 17 (CDH17) using its proprietary IDDC technology platform [1] Company Summary - The company announced the receipt of a Clinical Research Continuation Notification from the FDA on August 18, indicating that the clinical trial for 7MW4911 can proceed [1] - 7MW4911 is developed based on the company's own intellectual property rights and represents a significant advancement in targeted cancer therapy [1]